Thirty-day in-hospital revascularization and mortality rates after acute myocardial infarction in seven Canadian provinces

Canadian Journal of Cardiology

Volumn 26, Issue 7, 2010, Pages

  Johansen, Helen ^a   Brien, Susan E ^b   Finès, Philippe ^a   Bernier, Julie ^a   Humphries, Karin ^c   Stukel, Therese A ^d   Ghali, William A ^b  

^a STATISTICS CANADA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Acute myocardial infarction; Administrative data; Mortality; Outcomes research; Revascularization

Indexed keywords

AGED; CANADA; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; EPIDEMIOLOGY; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CANADA; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INPATIENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; SURVIVAL RATE;

EID: 77956892619     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)70415-3     Document Type: Article

References (33)

1. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet 2003;361:847-58.
2. Brown M, D'Haem C, Berkompas D, Cohn JM. Acute interventions for myocardial reperfusion. Emerg Med Clin N Am 1998;16:566-81.
3. Pais PS. Early intervention and prevention of myocardial infarction. J Hyperten 2006;24(Suppl 2):S25-S30.
4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
5. Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, Wallentin L. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: A follow-up study. Lancet 2006;368:998-1004.
6. Lagerqvist B, Husted S, Kontny F, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2002;40:1902-14.
7. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): An open, prospective, randomised, multicentre trial. Lancet 2008;371:559-68.
8. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
9. Hoenig MR, Doust J, Aroney CN, Scott IA. Early invasive versus conservative strategies for unstable angina and non-ST-elevation myocardial infarction in the stent era. Cochrane Database Syst Rev 2006;(3):CD004815. (Rev)
10. Johansen H, Bernier J, Fines P, Brien S, Ghali W, Wolfson M; Canadian Cardiovascular Outcomes Research Team. Variations by health region in treatment and survival after heart attack. Health Rep 2009;20:29-34.
11. Manual of the International Statistical Classification of Disease, Injuries and Death. Based on the recommendations of the Ninth Revision Conference, 1975. Geneva: World Health Organization, 1977.
12. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Geneva: World Health Organization, 1992.
13. Commission on Professional and Hospital Activities. Annotated ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification. Ann Arbor: Edward Brothers Inc, 1986.
14. Canadian Institute of Health Information. International Statistical Classification of Diseases and Related Health Problems. ICD-10-CA/CCI. Ottawa: The Institute, 2003.
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
16. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998;24:323-55.
17. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. J Am Med Assoc 1997;278:2093-8.
18. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations. Circulation 1999;100:1016-30.
19. Spertus JA, Radford MJ, Every NR, Ellerbeck EF, Peterson ED, Krumholz HM. Challenges and opportunities in quantifying the quality of care for acute myocardial infarction. Circulation 2003;107:1681-91.
20. Cox DA, Stone GW, Grines CL, et al. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC Trial). Am J Cardiol 2006;98:331-7.
21. Stenestrand U, Wallentin L. Early revascularization and 1-year survival in 14-day survivors of acute myocardial infarction: A prospective cohort study. Lancet 2002;359:1805-11.
22. Jackevicius CA, Alter D, Cox J, et al. Acute treatment of myocardial infarction in Canada 1999-2002. Can J Cardiol 2005;21:145-52.
23. Feldman RD, Campbell N, Larochelle P, et al. 1999 Canadian recommendations for the management of hypertension. CMAJ 1999;161:S1-S14.
24. Expert Panel on Detection EaToHBCiA. Executive summary of the Third Report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
26. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003;168:553-7.
27. Jackevicius CA, Tu K, Filate W, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol 2003;19:1359-66.
28. Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol 2002;88:100-7.
29. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96(Suppl):24F-33F.
30. Canadian Institute for Health Information. Health Care in Canada 2001. Ottawa: Canadian Institute for Health Information, 2001.
31. Austin D, Oldroyd KG, Holmes DR Jr, et al; APPROACH Investigators; Belgian Working Group on Invasive Cardiology; Mayo Clinic PCI Registry; Scottish Coronary Revascularisation Registry. Drug-eluting stents: A study of international practice. Am Heart J 2009;158:576-84.
32. Poulin F, Rinfret S, Gobeil F. Potential shift from coronary bypass surgery to percutaneous coronary intervention for multivessel disease and its economic impact in the drug-eluting stent era. Can J Cardiol 2007;23:1139-45.
33. Canadian Intergovernment Conference Secretariat. 2004. First Ministers' Meeting on the Future of Health Care: Investments for health and new funding levels - a 10-year plan to strengthen health care. 〈www.scics.gc.ca/ cinfo04/800042005 e.pdf〉 (Accessed on April 5, 2010).